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I. Abstract 
 
Although cannabinoid drugs have been used for thousands of years both recreationally 
and therapeutically, little has been known about their mechanisms of action until recently.  Since 
the discovery of the endogenous cannabinoid CB1 receptor in 1988, the behavioral profile of 
cannabinoid receptor ligands has been much more thoroughly defined.  Cannabinoid CB1
agonists have been shown to produce a variety of behavioral effects including suppression of 
locomotion, catalepsy, hypothermia, and analgesia.  Research has also demonstrated that these 
behavioral effects can be inhibited by CB1 receptor antagonists including SR 141716 and AM 
251.  Although behavioral indicators of anxiety including thigmotaxis have been observed in 
several different paradigms, there is inconclusive and often times contradictory evidence to 
define the role of anxiety in CB1 receptor activation.  The present study addressed the behavioral 
profile of AM 4054, a novel full agonist at the CB1 receptor, as well as the ability of the CB1
antagonist AM 251 to reverse these effects.  To further identify and expand research on the 
suppression of locomotion and induction of thigmotaxis with the administration of a CB1 agonist, 
experiment 1 was conducted in the open field.  In this experiment, each rat (n=40) was randomly 
assigned one of the five treatments: vehicle, 0.16, 0.32, 0.64, or 1.25 mg/kg AM 4054.  After a 
30 minute pre-treatment, each subject was tested in the open field for 18 minutes.  Results 
indicated that AM 4054 produced a dose-related suppression of locomotion as well as the subtle 
presence of thigmotaxis in two out of four doses.  In experiment 2, subjects (n=40) received 
either vehicle or 2.0 or 4.0 mg/kg AM 251 60 minutes prior to testing.  After 30 minutes, the 
subjects were given either a 0.3 mg/kg dose of AM 4054 or vehicle.  After a total pretreatment 
duration of 60 minutes, the animals were tested on a battery of tasks including an 18 minute 
session in locomotor boxes.  Experiment 2 was a continuation of a previous study conducted in 
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the same lab, which confirmed the effects of AM 4054 on this tetrad of tasks as being consistent 
with other cannabinoid agonists.  In this experiment the effects of AM 4054 were reversed by the 
administration of the CB1 antagonist AM 251.  Past studies have shown that AM 4054 is a highly 
potent drug with behavioral actions similar to other cannabinoid CB1 agonists.  Furthermore, AM 
4054 can be a useful drug in future studies, and has potential therapeutic value for the treatment 
of various conditions. 
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II. Introduction 
 Throughout history, the marijuana plant (Cannabis sativa) has been used both 
medicinally and recreationally in many different cultures around the world.  Despite the often 
negative view of this drug as one of the most commonly abused substances in the United States, 
there has been heated political debate for and against the medicinal use of the Cannabis plant for 
the treatment of various health conditions.  Cannabis has been used anecdotally for more than 
five thousand years to treat a variety of conditions including hysteria, delirium, insomnia, nausea, 
anorexia, glaucoma, and pain (Burns and Ineck, 2006).  A relatively safe drug with virtually no 
potential for overdose, the marijuana plant can be an important treatment.       
 During the beginning of the 20th century, cannabis was commonly prescribed in the US 
and Europe to treat pain, pertussis, asthma, gastrointestinal disorders, Grave's disease, diarrhea, 
malaria, and as a sedative (Grotenhermen and Russo, 2002).  In an attempt to suppress the abuse 
of the cannabis plant, the Controlled Substances Act of 1970 defined marijuana as a Schedule I 
drug, and classified cannabis as drug with no legitimate medicinal value (Burns and Ineck, 
2006).  As countless new studies continue to suggest otherwise, legislation has been passed in 
several states to allow the prescription of marijuana for select patients.  Many practitioners are 
reluctant to recommend its use however, due to intense scrutiny and disapproval by the federal 
government (Burns and Ineck, 2006).  Despite the legal and political controversy behind 
cannabis drugs, the history of marijuana has been well documented and noted within the medical 
field, and cannabis is still used medicinally all over the world for the treatment of several 
different medical conditions. 
 Research has shown that marijuana contains several active and inactive cannabinoids, the 
primary active ingredient being delta-9-tetrahydracannabinol (THC).  Cannabidiol, another 
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major cannabinoid component of marijuana thought to have anti-oxidant and anti-inflammatory 
properties without the psychoactive effects of THC, was identified in 1934 (McPartland and 
Russo, 2001).  With the discovery of THC in 1964, research on the cannabis plant moved to a 
much higher level (Mechoulam and Gaoni, 1967).  For several years however, there were 
misconceptions about the pharmacologic properties of THC and Marijuana, and it was long 
thought that they disrupted cellular membranes, rather than being associated with a specific 
receptor (Munro et al., 1993).   
For almost thirty years, the primary mechanism of action for THC was not known, and it 
was not until recently that endogenous cannabinoid receptors were identified in the central and 
peripheral nervous systems.  With the discovery of these endocannabinoid receptors, new 
Cannabinoid agonists have been developed with high affinities for these receptors.  Although 
many new drugs have been developed, few have been studied for their effects on human 
subjects.  Ajulemic acid (CT-3) has been tested on humans, and has been found to produce fewer 
psychoactive effects while maintaining analgesic potential (Karst et al., 2003; Burstein et al., 
2004).  CT-3 is an analog of a THC metabolite, and some studies have shown that it may have 
anti-inflammatory effects (Zurier et al., 1998).  In recent years there has been an effort to 
develop cannabinoid drugs that produce fewer psychoactive effects but still maintain their 
medical value.    
 Since the discovery of the cannabinoid CB1 receptor in 1988 and the subsequent 
discovery of the cannabinoid CB2 receptor in 1993, there has been a new focus of research 
conducted on the endocannabinoid system (Beardsley 2005).  In 1992, the endogenous 
cannabinoid receptor ligand arachidonoylethanolamide (anandamide) was found to occur 
naturally in the brain (Devane et al., 1992).  With the identification of endogenous agonists, 
McClure, ED   5
researchers have studied the biological role of endocannabinoid systems with specific emphasis 
on appetite, eating behavior, and body weight regulation (Kirkham 2005). 
CB1 receptor activation has been a major area of interest while brain expression of CB2
receptors has been much less emphasized in research over the years (Gong et al., 2005).  This is 
due mostly to the fact that CB2 receptor activation has traditionally been associated with immune 
tissues in the peripheral nervous system.  More recent literature on the other hand shows the 
expression of CB2 receptor messenger RNA and protein localization on brainstem neurons as 
well as the presence of functional CB2 receptors in the brainstem (Sickle et al., 2005).  These 
results are in contrast to numerous previous studies that failed to detect the presence of CB2
receptors in the brain (Gong et al., 2005).  CB1 receptors on the other hand, do occur in the 
periphery, but are more commonly associated with the tissues of the central nervous system.  
Several studies have been conducted over the years to localize CB1 receptors to various parts of 
the brain, and few have been successful in doing so (Fusco et al., 2004).   Immunohistochemical 
studies with light and confocal microscopy however, have been helpful in identifying various 
regions in the brain with dense CB1 expression (Fusco et al. 2004).  Research has indicated that 
endocannabinoid CB1 receptors are found in CNS areas such as the basal ganglia, cerebellum, 
hippocampus, hypothalamus, nucleus accumbens, amygdala, cerebral cortex, brain stem, and 
spinal cord (Ferund et al., 2003).     
 Early cannabinoid agonists, created by pharmaceutical groups to have similar binding 
properties to delta-9-THC, built a foundation for early cannabinoid research.  Noted for their 
high affinities for endogenous CB1 receptors, several compounds have been created including CP 
55,940 (Johnson and Melvin, 1986), WIN 55,212-2 (Ward et al., 1989), and AM 411 
(McLaughlin et al., 2005).  Within the past decade, researchers have developed new cannabinoid 
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agonists with variable affinities for both CB1 and CB2 receptors.  Greatly varying in potency, 
these drugs bind to the endocannabinoid receptors and mimic the actions of endogenous 
cannabinoids.  The development of CB1 agonists provides critical research tools for studying 
cannabinoid receptor function as well as any therapeutic benefits these compounds may have for 
use in the medical field (McLaughlin et al., 2005).   
 Over the past several years, research on cannabinoid receptors has generated interest in 
the pharmaceutical industry.  With the development of cannabinoid agonists, researchers have 
been able to study the behavioral effects of cannabinoid receptor activation and the possible 
medicinal benefits of cannabinoid drugs.  In recent years, cannabinoid antagonists have been a 
major focus of research. With the identification of the first CB1 selective antagonist SR141716 
in 1994, a significant body of research has investigated the possible use of cannabinoid 
antagonists (Beardsley 2005).  Cannabinoid receptors in the CNS have been implicated in the 
control of appetite, cognition, mood and drug dependence; recent findings support the hypothesis 
that CB1 receptor antagonism might be associated with antidepressant and anti-stress effects 
(Witkin et al., 2005).  In addition, studies have been conducted to evaluate the use of CB1
antagonists as potential appetite suppressants. 
 CB1 receptor antagonists are believed to have therapeutic potential as appetite 
suppressants because they affect food intake at doses that do not produce side effects such as 
ataxia or decreased locomotion (McLaughlin et al., 2005).  However, the specific mechanisms 
underlying food intake reduction produced by CB1 antagonists are not well understood 
(McLaughlin et al., 2005).  Still, the question of whether or not increases in nausea are an 
important part of appetite suppression needs to be considered.  A recent study concluded that the 
CB1 antagonist AM 251 may reduce food intake by inducing nausea or malaise, but not because 
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of motor slowing or incoordination related to feeding (McLaughlin et al., 2005).  The prospect of 
CB1 antagonists and their use as appetite suppressants in the human population has generated 
much interest in the pharmaceutical industry.  Before these drugs may be used for weight loss in 
humans, more research must be done.  
Research on cannabinoid CB1 antagonists and their role in the treatment of mood 
disorders and substance abuse is greatly expanding.  In a recent study by Witkin et al. (2005), 
CB1 receptor antagonists were noted for their promising effects in clinical studies, where they 
were found to treat comorbid symptoms of depression such as cognitive deficiencies, weight 
gain, impulsivity, and dependence disorders. 
In the study of cannabinoid systems and their role in modulating anxiety, it is important 
to highlight the highly inconsistent, often contradictory effects of cannabinoid receptor 
manipulations on anxiety related behaviors (Rodgers et al., 2005).  Despite years of research, the 
mechanisms behind cannabinoid modulation of anxiety remain poorly understood (Genn et al., 
2004).  Several studies have proposed that cannabinoid agonists are anxiolytic (Haller et al., 
2002), while others have shown the anxiogenic effects of cannabinoid drugs (Arevalo et al., 
2001; Genn et al., 2004).  
 The analgesic properties of CB1 agonists present a possible pain relieving alternative for 
opioid drug use in the medical field.  Opioid drugs including morphine have severe dependency 
properties that pose serious problems in the treatment of chronic pain.  Chronic pain often 
requires a polypharmaceutical approach to management, and cannabinoids are a potential 
addition to the arsenal of treatment options (Burns and Ineck, 2006).  In addition, Cannabinoids 
provide a potential approach to pain management with a novel therapeutic target and mechanism, 
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and are a particularly attractive prospect because they have a favorable safety profile (Burns and 
Ineck, 2006). 
 In contradiction to the belief that cannabinoid drugs are neurodegenerative, these drugs 
have actually been found to protect against neurotoxicity in several different paradigms (Zhuang 
et al., 2005).  In particular, a recent study demonstrated that cultured rat hippocampal neurons 
were protected from excitotoxic degeneration by pretreatment with CB1 agonists such as THC 
and WIN 55,212-2 (Zhuang et al., 2005).  A major point of interest in this study was that the 
compounds were effective in preventing cell death even if administered prior to the neurotoxin 
exposure (Zhuang et al., 2005).  In addition to their neuroprotective properties, cannabinoid 
agonists have been shown to be useful in the treatment of several diseases including Tourette’s 
Syndrome (Muller-Vahl et al., 2002), multiple sclerosis (Baker et al., 2001), and Alzheimer’s 
disease (Volicer et al., 1997).     
Cannabinoid drugs and their role in cancer treatment has also been a growing research 
topic.  In human breast cancer patients, it has been found that the endocannabinoid system with 
specific emphasis on anandamide, regulates cell proliferation in breast cancer cells (Grimaldi et 
al., 2005).  Cancer chemo therapy often produces nausea and decreased appetite which may lead 
to malnourishment.  As a possible solution, appetite studies have shown that CB1 receptor 
agonists including delta-9-THC increase feeding in rats and humans (McLaughlin et al., 2003).  
Many properties of CB1 agonists make them useful drugs in treating a variety of health 
conditions and disorders.   
 In the past, cannabinoid CB1 receptor agonists have been shown to produce several 
behavioral actions including locomotor suppression, catalepsy, memory and attentional 
impairments, reduced reactivity to painful stimuli (analgesia), ataxia, and hyperphagia (Childers 
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and Breivogel, 1998).  Numerous other papers have highlighted the suppression of operant 
responding in rats after the administration of a CB1 agonist.  In a study by Carriero et al. (1997), 
four cannabinoid agonists suppressed operant lever pressing at moderate to high doses.   
 In the 1991 paper by Martin et al., a clear behavioral profile for cannabinoid agonists was 
developed.  According to this study, suppression of spontaneous locomotion, induction of 
catalepsy, hypothermia, and analgesia, comprises a tetrad of behaviors characteristic of CB1
agonists (Martin et al., 1991).  In a more recent paper, Wiley and Martin stressed the importance 
of classifying cannabinoids based on this tetrad of tasks and showing the reversal of these effects 
with the use of a cannabinoid antagonist (2003).  In addition, a necessary component for the 
classification of a CB1 agonist is that it displays similar potency on all four tests in the tetrad 
(Wiley and Martin, 2003).  
 The present study was conducted to show the behavioral profile of AM 4054, a novel 
agonist at the CB1 receptor, and the results of its co-administration with AM 251.  Because CB1
agonists are often found to produce anxiogenic effects (Arevalo et al., 2001; Genn et al., 2004), 
locomotor suppression in the open field may reflect effects related to anxiety.  Thigmotaxis, 
which refers to an animal’s tendency to stay close to the outside of the open field when 
experiencing anxiety, was an important component of the study.  Experiment 1 addressed the 
question of whether or not AM 4054 suppressed locomotion in the open field, and if thigmotaxis 
occurred in moderate to high doses of the drug.  Experiment 2 studied the ability of the CB1
antagonist AM 251 to reverse suppression of locomotion, catalepsy, hypothermia, and analgesia 
induced by the CB1 agonist AM 4054.  This experiment was an extension of past research that 
confirmed AM 4054 as a potent cannabinoid that had an effect on the tetrad of tasks.    
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III. Materials and Methods 
Subjects 
The present experiments were conducted using adult male Sprague-Dawley rats (Harlan 
Sprague Dawley, Indianapolis, IN) with no prior drug experience; (total n = 80).  These rats each 
weighed 300 – 450 grams on the day of testing.  All rats were housed in a colony room with a 12 
hour light-dark cycle and kept at a temperature of approximately 22-25°C.  Throughout the 
course of these experiments, animals received ad libitum access to water and standard laboratory 
chow.  Animal protocols were approved by the institutional animal care and use committee, and 
all experimental methods were in accordance with the Guide for the Care and Use of Laboratory 
Animals (National Research Council, 1996). 
 
Drugs 
AM 4054 and AM 251 were synthesized in the laboratory of Alex Makriyannis, in the 
School of Pharmacy at Northeastern University.  All injections were administered i.p.  Vehicle 
for these compounds consisted of dimethyl-sulfoxide (DMSO), Tween-80 (both from Sigma, St. 
Louis, MO), and 0.9% saline in a 1:2:7 ratio.  For experiment 1, AM 4054 was administered in a 
dose range of 0.16-1.25 mg/kg i.p.  In experiment 2, AM4054 was administered at a single dose 
of 0.3 mg/kg i.p.  To reverse the effects of AM 4054 in experiment 2, AM 251 was administered 
in a dose of either 2.0 or 4.0 mg/kg.   These doses were determined by extensive pilot studies.  
 
Behavioral Procedures 
Assessment of open field locomotion and relative interior activity
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The open field chamber was constructed with a square wooden floor (115 cm X 115 cm) 
painted black with white lines every 23 cm, forming a five-by-five grid.  A clear Plexiglas sheet 
covered the floor of the open field.  The walls of the open field were 44 cm in height.  Sessions 
were 18 minutes long and the rats were tested in a darkened room with dim red lamps above two 
corners.  Both the experimental room and the open field apparatus were novel to the subjects, 
and each subject was tested only once.  At the start of the 18 minute session, the rats were placed 
in one of the four corners of the open field and were faced toward the center.  Blind to treatment, 
an observer separately counted inner and outer horizontal crossings, which were defined by the 
movement of all four paws from one block square to another.  A hand counter was used to make 
these counts.  Outer crossings were defined by movements into one of the 16 squares adjacent to 
the walls, either from another outer square along the wall or from an inner square.  Inner 
crossings were defined as movements into and within the nine center blocks of the open field 
which did not run along the walls. 
 
Assessment of locomotion, catalepsy, hypothermia, and analgesia
For the assessment of locomotor activity, rats were placed in small locomotor chambers 
(28 × 28 × 28 cm).  The floor in each of the four chambers consisted of two wire mesh panels 
(27 × 13 cm) connected by a metal rod though the center.  This metal rod was a fulcrum for the 
floor panels, which were able to move freely.  Locomotion by the subjects from one area in the 
chamber to another produced a deflection of one or more floor panels, which closed one or more 
of four microswitches mounted on the outside of the chamber.  These microswitch closures were 
detected and counted by an external computer that ran a custom program previously written in 
QBasic, by means of an interface (Med Associates).  Animals were tested in 18 minute sessions.  
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In order to ensure a high baseline of locomotor counts, the chambers were novel to the subjects 
at the time of testing.  Subjects were moved to an adjoining room immediately following the 
locomotion session, and were allowed to habituate for 5 minutes.  Subjects were then tested for 
catalepsy.  A thin metal bar fixed at 13 centimeters above a wooden stand was used by placing 
both of the subject’s forelimbs over it with both hind limbs on the wooden stand.  Subjects were 
timed for latency to remove one or both forelimbs, or to jump onto the bar.  Two trials were 
taken for each subject, and latencies were summed.  As a measure of analgesia, subjects were 
tested for latency on a tail-flick apparatus that inflicted a varying level of pain (Ugo Basile, 
Italy).  In order to prevent spontaneous movement, the rats were wrapped lightly in a cloth towel.  
Each subject's tail was placed in contact with a heat source that contained a photosensor which 
was activated using a foot pedal.  Any movement of the tail was detected by the photosensor, 
which then turned off the heat source and stopped a built-in timer.  A maximum duration of 10 
seconds was set to prevent damage to the rats.  To measure differing levels of hypothermia, each 
subject's temperature was taken with a pliable, water-resistant thermistor that was inserted 6 cm 
into the animal's rectum.  A digital thermometer was connected to the thermistor, and recorded 
the temperatures.  Temperatures were allowed to stabilize for at least 5 seconds before being 
recorded. 
 
Experiments 
Experiment 1:  Effects of AM 4054 on spontaneous locomotion and thigmotaxis in the open field
In the following experiment, the effects of AM 4054 on spontaneous locomotion and 
thigmotaxis were assessed.  Rats (n=40) were handled for five days before testing.  Each rat was 
randomly assigned one of the five treatments: vehicle, 0.16, 0.32, 0.64, or 1.25 mg/kg AM 4054.  
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After a 30 minute pre-treatment, each subject was tested in the open field for 18 minutes.  The 
number of inner and outer line crossings were counted and recorded. 
Experiment 2:  Reversal of AM 4054 behavioral effects with CB1 antagonist AM 251
In experiment 2, a new group of animals was randomly assigned to one of five different 
treatment groups to demonstrate the reversal of the behavioral effects of AM 4054, using the CB1
antagonist AM 251.  Subjects (n=40) received either vehicle or 2.0 or 4.0 mg/kg AM 251 60 
minutes prior to testing.  After 30 minutes, the subjects were given either a 0.3 mg/kg dose of 
AM 4054 or vehicle.  After a total pretreatment duration of 60 minutes, the animals were tested 
on a battery of tasks including an 18 minute session in locomotor boxes.   
 
Data Analyses 
Behavioral data for experiment 1 and each part of the tetrad were analyzed separately 
using a between subjects one-way ANOVA with dose as the between subjects factor.  In cases 
where assumptions of homogeneity of variance were violated, the nonparametric Kruskal-Wallis 
test was used.  Individual dose effects were analyzed using planned comparisons, which 
compared the effects of each dose to the effects of vehicle.  For the reversal tetrad in experiment 
2, a behavioral effect of AM 4054 was considered reversed by AM 251 if planned comparisons 
suggested the group that received AM 251 plus AM 4054 significantly differed from the group 
receiving AM 4054 only.  To perform the present data analysis, a computerized statistical 
program (SPSS 10.1 for Windows) was used. 
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IV. Results 
Experiment 1:  Effects of AM 4054 on spontaneous locomotion and thigmotaxis in the open field 
AM 4054 significantly suppressed locomotion on the inside (Fig. 1; (F(4,35)=24.27, 
p<0.001) as well as locomotion on the outside portions of the open field (Fig 2; (F(4,35)=121.16, 
p<0.001).  Planned comparisons revealed significant differences between all doses of AM 4054 
in comparison to vehicle. 
Experiment 2:  Reversal of AM 4054 behavioral effects with CB1 antagonist AM 251
The behavioral effects of AM 4054 were reversed with the co-administration of the CB1
selective antagonist AM 251.  With catalepsy, an ANOVA revealed a significant overall group 
difference (Fig. 3; F(4,35)= 9.44, p<0.01).  AM 251 alone had no significant effect, while AM 
4054 caused a significant induction of catalepsy compared to vehicle (p<0.01).  Catalepsy 
induced by AM 4054 was significantly reduced by co-administration of AM 251 at both the 2.0 
and 4.0 mg/kg doses (p<.0.01).  In the tail-flick analgesia test (Fig. 4), there was a significant 
overall effect (F(4,35)=9.5, p<.0.001).   AM 251 alone had a significant effect (p<0.05), and AM 
4054 caused an increase in tail-flick latency (p<0.01).  AM 4054-induced analgesia was 
significantly reduced by co-administration of AM 251 at both the 2.0 and 4.0 mg/kg doses 
(p<0.01; p<0.05).  For assessment of body temperature (Fig. 5), temperatures were found to be 
significantly different from group to group (F(4,35)=28.68, p<0.001).  AM 251 alone had no 
significant effect, while AM 4054 caused a significant reduction in body temperatures compared 
to vehicle (p<0.01).  AM 4054-induced hypothermia was significantly reduced by co-
administration of AM 251 at both the 2.0 and 4.0 mg/kg doses (p<0.01).  In the locomotor 
chambers, AM 4054 alone did have a significant effect on locomotion (p<0.01).  The 
suppression of locomotion induced by AM 4054 was not significantly reversed by AM 251 at 
McClure, ED   15
either the 2.0 or 4.0 mg/kg dose.  The Kruskal-Wallis test revealed a significant dose-related 
effect across all groups (p<0.01).      
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V. Discussion 
Previous research characterized AM 4054 as a potent CB1 selective cannabinoid agonist 
with characteristic effects on the tetrad test, including locomotor suppression, catalepsy, 
analgesia, and hypothermia (Martin et al., 1991).  In the present study, some of these effects 
were reversed with the co-administration of the CB1 selective antagoinist AM 251 at doses that 
are behaviorally active in rats (McLaughlin et al., 2003).  
Characterized by potency on all four tests of the tetrad, the behavioral effects of CB1
agonists must be reversed by a CB1 antagonist in order to fit the profile (Rinaldi-Carmona et al., 
1994).  In order to classify AM 4054 as a cannabinoid agonist, a tetrad was conducted.  Having 
similar potency on all four levels of the tetrad (data not shown), it was hypothesized that a 
cannabinoid antagonist such as AM 251 would reverse these effects.  Both the 2.0 mg/kg dose 
and 4.0 mg/kg dose of AM 251 significantly reversed the effects of AM4054 on three of the four 
tasks.   
In the past, high doses of CB1 antagonists including SR 141716A have been found to 
inhibit open field ambulation (Jarbe et al., 2002).  In addition, past research has suggested that 
AM 251 alone produces a significant suppression of locomotion (McLaughlin et al., 2005).  
Subjects treated with both AM 4054 and AM 251 produced locomotor counts similar to vehicle, 
suggesting that the locomotor suppressant effects of both drugs offset each other. 
Thigmotaxis, an animal’s tendency to avoid the inner region of the open field and 
ambulate near the high walls of the outside region, has been demonstrated with anxiogenic drugs 
including benzodiazepine inverse agonists (Prut and Belzung, 2003).  In the past, it has been 
suggested that changes in relative interior activity in the open field task can be used as a 
behavioral determinant of anxiolytic or anxiogenic effects of drugs (Prut and Belzung, 2003).  In 
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the present study, thigmotaxis was observed at the 0.16 and 0.31 mg/kg doses of AM 4054.  AM 
4054 reduced locomotion in the open field with little indication of thigmotaxis at doses other 
than 0.16 and 0.31 mg/kg.  This is not to say however that an anxiogenic effect did not exist.  All 
doses of AM 4054 used in this study caused a profound decrease in locomotor counts in both the 
inner and outer portions of the open field.  There was, however, a slightly more defined 
suppression of inside crossings than outside crossings, perhaps suggesting an anxiogenic effect 
of AM 4054 at doses that also suppress motor activity.  It is also important to consider 
differences between doses.  In the past, it has been suggested that cannabinoid agonists produce 
anxiolytic effects at low doses, but anxiogenic effects at higher doses (Genn et al., 2004).  In the 
present study, the 0.3 mg/kg dose of AM4054 that suppressed locomotion in the locomotor cages 
also reduced inside and outside crossings in the open field.  Because interior and exterior counts 
were analyzed separately, it was possible to compare the effects more efficiently.  Since exterior 
activity was significantly suppressed at all doses, an overall motor effect was shown.  Combined 
with the reduction in locomotion and induction of catalepsy in experiment 2, it is reasonable to 
suggest that AM 4054 inhibits locomotion by impairing motor control, but that the drug does in 
fact produce anxiogenic effects in the same dose range. 
In the past it has been concluded that AM4054 produces behavioral effects consistent 
with other cannabinoid agonists that have their effects at the CB1 receptor.  In the future, AM 
4054 can be a useful tool for further understanding CB1 receptor activation as well as aiding the 
development of new cannabinoid agonists.  AM 251 continues to be a useful tool for classifying 
new cannabinoid agonists and conducting behavioral tests.  Future studies should further explore 
the anxiety-related properties of cannabinoid drugs in order to more fully understand 
endocannabinoid system roles in regulating anxiety.                  
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VII. Figure Captions 
Figure 1. AM 4054 reduced inside crossings in the open field.  Data points represent mean ( ± 
S.E.M.) number of total inside crossings in the open field.  **p<0.01 difference between dose of 
AM 4054 and vehicle using planned comparisons. 
 
Figure 2. AM 4054 reduced outside crossings in the open field.  Data points represent mean ( ± 
S.E.M.) number of total outside crossings in the open field.  **p<0.01 difference between dose 
of AM 4054 and vehicle using planned comparisons. 
 
Figure 3. AM 251 reverses catalepsy induced by AM 4054.  Bars represent group means ( ± 
S.E.M.).  **p<0.01 difference between AM 4054 alone and vehicle.  ‡p<0.01 difference between 
AM 251-pretreated animals and AM 4054 alone using planned comparisons. 
 
Figure 4.  AM 251 reverses analgesic effects of AM 4054.  Bars represent group means ( ± 
S.E.M.).  *p<0.05; **p<0.01 difference between AM 4054 alone and vehicle.  †p<0.05; ‡p<0.01 
difference between AM 251-pretreated animals and AM 4054 alone using planned comparisons. 
 
Figure 5.  AM 251 reverses hypothermia induced by AM 4054.  Bars represent group means ( ± 
S.E.M.).  **p<0.01 difference between AM 4054 alone and vehicle.  ‡p<0.01 difference between 
AM 251-pretreated animals and AM 4054 alone using planned comparisons. 
 
Figure 6. AM 251 reverses locomotor suppression induced by AM 4054.  Bars represent group 
means ( ± S.E.M.).  **p<0.01 difference between AM 4054 alone and vehicle. 
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Figure 3. 
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